Aberrant Stem Cell and Developmental Programs in Pediatric Leukemia

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2024 Apr 11

PMID 38601080

Authors

Rebecca E Ling

Joe W Cross

Anindita Roy

Affiliations

Soon will be listed here.

Abstract

Hematopoiesis is a finely orchestrated process, whereby hematopoietic stem cells give rise to all mature blood cells. Crucially, they maintain the ability to self-renew and/or differentiate to replenish downstream progeny. This process starts at an embryonic stage and continues throughout the human lifespan. Blood cancers such as leukemia occur when normal hematopoiesis is disrupted, leading to uncontrolled proliferation and a block in differentiation of progenitors of a particular lineage (myeloid or lymphoid). Although normal stem cell programs are crucial for tissue homeostasis, these can be co-opted in many cancers, including leukemia. Myeloid or lymphoid leukemias often display stem cell-like properties that not only allow proliferation and survival of leukemic blasts but also enable them to escape treatments currently employed to treat patients. In addition, some leukemias, especially in children, have a fetal stem cell profile, which may reflect the developmental origins of the disease. Aberrant fetal stem cell programs necessary for leukemia maintenance are particularly attractive therapeutic targets. Understanding how hijacked stem cell programs lead to aberrant gene expression in place and time, and drive the biology of leukemia, will help us develop the best treatment strategies for patients.

References

Porcher C, Chagraoui H, Kristiansen M . SCL/TAL1: a multifaceted regulator from blood development to disease. Blood. 2017; 129(15):2051-2060. DOI: 10.1182/blood-2016-12-754051. View

Charbord P, Tavian M, Humeau L, Peault B . Early ontogeny of the human marrow from long bones: an immunohistochemical study of hematopoiesis and its microenvironment. Blood. 1996; 87(10):4109-19. View

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Abedin S, Badar T, Gauger K, Michaelis L, Runaas L, Carlson K . Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia. Leuk Res. 2022; 123:106984. DOI: 10.1016/j.leukres.2022.106984. View

Bhansali R, Rammohan M, Lee P, Laurent A, Wen Q, Suraneni P . DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3. J Clin Invest. 2021; 131(1). PMC: 7773384. DOI: 10.1172/JCI135937. View

Marquis M, Beaubois C, Lavallee V, Abrahamowicz M, Danieli C, Lemieux S . High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia. Blood Cancer J. 2018; 8(8):68. PMC: 6066481. DOI: 10.1038/s41408-018-0103-6. View

Agraz-Doblas A, Bueno C, Bashford-Rogers R, Roy A, Schneider P, Bardini M . Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis. Haematologica. 2019; 104(6):1176-1188. PMC: 6545849. DOI: 10.3324/haematol.2018.206375. View

Freese N, Lam B, Staton M, Scott A, Chapman S . A novel gain-of-function mutation of the proneural IRX1 and IRX2 genes disrupts axis elongation in the Araucana rumpless chicken. PLoS One. 2014; 9(11):e112364. PMC: 4221472. DOI: 10.1371/journal.pone.0112364. View

Viswanathan S, Powers J, Einhorn W, Hoshida Y, Ng T, Toffanin S . Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009; 41(7):843-8. PMC: 2757943. DOI: 10.1038/ng.392. View

10.

Malouf C, Antunes E, ODwyer M, Jakobczyk H, Sahm F, Landua S . miR-130b and miR-128a are essential lineage-specific codrivers of t(4;11) MLL-AF4 acute leukemia. Blood. 2021; 138(21):2066-2092. DOI: 10.1182/blood.2020006610. View

11.

Efanov A, Zanesi N, Coppola V, Nuovo G, Bolon B, Wernicle-Jameson D . Human HMGA2 protein overexpressed in mice induces precursor T-cell lymphoblastic leukemia. Blood Cancer J. 2014; 4:e227. PMC: 4219444. DOI: 10.1038/bcj.2014.46. View

12.

Popescu D, Botting R, Stephenson E, Green K, Webb S, Jardine L . Decoding human fetal liver haematopoiesis. Nature. 2019; 574(7778):365-371. PMC: 6861135. DOI: 10.1038/s41586-019-1652-y. View

13.

Drabkin H, Parsy C, Ferguson K, Guilhot F, Lacotte L, Roy L . Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia. 2002; 16(2):186-95. DOI: 10.1038/sj.leu.2402354. View

14.

Tolba F, Foda M, Kamal H, Elshabrawy D . Expression of CD133 in acute leukemia. Med Oncol. 2013; 30(2):527. DOI: 10.1007/s12032-013-0527-6. View

15.

Brunetti L, Gundry M, Sorcini D, Guzman A, Huang Y, Ramabadran R . Mutant NPM1 Maintains the Leukemic State through HOX Expression. Cancer Cell. 2018; 34(3):499-512.e9. PMC: 6159911. DOI: 10.1016/j.ccell.2018.08.005. View

16.

Vora P, Venugopal C, Salim S, Tatari N, Bakhshinyan D, Singh M . The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Cell Stem Cell. 2020; 26(6):832-844.e6. DOI: 10.1016/j.stem.2020.04.008. View

17.

Bueno C, Velasco-Hernandez T, Gutierrez-Aguera F, Zanetti S, Baroni M, Sanchez-Martinez D . CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity. Leukemia. 2019; 33(8):2090-2125. PMC: 6756031. DOI: 10.1038/s41375-019-0418-8. View

18.

Stoskus M, Gineikiene E, Valceckiene V, Valatkaite B, Pileckyte R, Griskevicius L . Identification of characteristic IGF2BP expression patterns in distinct B-ALL entities. Blood Cells Mol Dis. 2011; 46(4):321-6. DOI: 10.1016/j.bcmd.2011.02.005. View

19.

Moison C, Spinella J, Chagraoui J, Lavallee V, Lehnertz B, Thiollier C . HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition. Blood Adv. 2022; 6(16):4793-4806. PMC: 9631656. DOI: 10.1182/bloodadvances.2021005828. View

20.

Ueno S, Lu J, He J, Li A, Zhang X, Ritz J . Aberrant expression of SALL4 in acute B cell lymphoblastic leukemia: mechanism, function, and implication for a potential novel therapeutic target. Exp Hematol. 2014; 42(4):307-316.e8. PMC: 4135469. DOI: 10.1016/j.exphem.2014.01.005. View